EV Biologics, Inc. (YECO)
USD 0.09
(-0.12%)
USD 0.09
(-0.12%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.11 Million USD | -91.63% |
| 2022 | 25.25 Million USD | 4.69% |
| 2021 | 24.12 Million USD | 1578.2% |
| 2020 | 1.43 Million USD | -95.13% |
| 2019 | 29.49 Million USD | 0.0% |
| 2017 | 16.71 Million USD | -33.6% |
| 2016 | 25.17 Million USD | -18.64% |
| 2015 | 30.94 Million USD | -3.02% |
| 2014 | 31.9 Million USD | 5.59% |
| 2013 | 30.21 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.37 Million USD | 7.74% |
| 2024 Q1 | 2.2 Million USD | 4.22% |
| 2024 Q3 | 2.42 Million USD | 2.03% |
| 2023 Q3 | 2.03 Million USD | -43.56% |
| 2023 Q4 | 2.11 Million USD | 3.69% |
| 2023 FY | 2.11 Million USD | -91.63% |
| 2023 Q1 | 3.52 Million USD | -86.04% |
| 2023 Q2 | 3.61 Million USD | 2.53% |
| 2022 Q3 | 24.97 Million USD | 0.44% |
| 2022 FY | 25.25 Million USD | 4.69% |
| 2022 Q4 | 25.25 Million USD | 1.13% |
| 2022 Q1 | 24.53 Million USD | 1.7% |
| 2022 Q2 | 24.86 Million USD | 1.34% |
| 2021 Q1 | 1.69 Million USD | 0.0% |
| 2021 Q4 | 24.12 Million USD | -0.13% |
| 2021 FY | 24.12 Million USD | 1578.2% |
| 2021 Q2 | 2.11 Million USD | 25.08% |
| 2021 Q3 | 24.15 Million USD | 1039.56% |
| 2020 FY | 1.43 Million USD | -95.13% |
| 2019 FY | 29.49 Million USD | 0.0% |
| 2017 Q1 | 29.55 Million USD | 5.91% |
| 2017 FY | 16.71 Million USD | -33.6% |
| 2017 Q2 | 29.55 Million USD | 0.0% |
| 2017 Q4 | 28.89 Million USD | 0.0% |
| 2016 Q1 | 23 Million USD | 13.4% |
| 2016 Q3 | 27.52 Million USD | 9.33% |
| 2016 Q2 | 25.17 Million USD | 9.43% |
| 2016 FY | 25.17 Million USD | -18.64% |
| 2016 Q4 | 27.9 Million USD | 1.39% |
| 2015 Q1 | 27.64 Million USD | 6.3% |
| 2015 FY | 30.94 Million USD | -3.02% |
| 2015 Q4 | 20.29 Million USD | -5.43% |
| 2015 Q3 | 21.45 Million USD | -30.66% |
| 2015 Q2 | 30.94 Million USD | 11.92% |
| 2014 Q4 | 26.01 Million USD | -31.02% |
| 2014 Q1 | 33.73 Million USD | -0.35% |
| 2014 Q2 | 31.9 Million USD | -5.4% |
| 2014 Q3 | 37.7 Million USD | 18.17% |
| 2014 FY | 31.9 Million USD | 5.59% |
| 2013 FY | 30.21 Million USD | 0.0% |
| 2013 Q2 | 30.21 Million USD | 0.0% |
| 2013 Q3 | - USD | -100.0% |
| 2013 Q4 | 33.85 Million USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -7609.944% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 77.656% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 97.081% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -161.509% |
| Rebus Holdings, Inc. | 5.24 Million USD | 59.651% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 96.416% |
| Qrons Inc. | 1.48 Million USD | -42.074% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -72.488% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 97.177% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -4632.121% |
| Skye Bioscience, Inc. | 14.07 Million USD | 84.97% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 96.032% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 77.927% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -401.715% |
| SQZ Biotechnologies Company | 50.03 Million USD | 95.773% |
| Intellipharmaceutics International Inc. | 12 Million USD | 82.387% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 45.083% |
| Mesoblast Limited | 188.44 Million USD | 98.878% |
| Marizyme, Inc. | 26.67 Million USD | 92.071% |
| Genus plc | 485 Million USD | 99.564% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 63.799% |
| Pharming Group N.V. | 244.07 Million USD | 99.133% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -5.221% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 15.946% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 44.34% |
| ContraFect Corporation | 32.53 Million USD | 93.498% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -6.751% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 44.742% |
| IMV Inc. | 37.93 Million USD | 94.424% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 82.043% |
| MultiCell Technologies, Inc. | 1617.67 USD | -130647.866% |
| ONE Bio Corp. | 27.49 Million USD | 92.308% |
| Accustem Sciences Inc. | 1.07 Million USD | -95.978% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 97.268% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | 8.13 Million USD | 73.994% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 97.45% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 58.899% |
| Biomind Labs Inc. | 1.49 Million USD | -41.135% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.218% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 76.609% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 88.507% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -47.509% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1388.489% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -951.666% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 63.189% |
| GB Sciences, Inc. | 5.41 Million USD | 60.959% |
| Alpha Cognition Inc. | 7.16 Million USD | 70.48% |
| HST Global, Inc. | 593.59 Thousand USD | -256.316% |
| CSL Limited | 18.62 Billion USD | 99.989% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -67.97% |
| Halberd Corporation | 728.71 Thousand USD | -190.245% |
| Enzolytics Inc. | 365.26 Million USD | 99.421% |
| Agentix Corp. | 2.51 Million USD | 15.753% |
| Resverlogix Corp. | 67.39 Million USD | 96.862% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -152.175% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.525% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -23.4% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 91.453% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 82.231% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 42.293% |
| AVAX Technologies, Inc. | 3.99 Million USD | 47.04% |
| Zenith Capital Corp. | 27.56 Thousand USD | -7571.91% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.84% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -786.249% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 43.361% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -210.659% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 22.0% |
| Kadimastem Ltd | 3.5 Million USD | 39.653% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -3060.168% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 95.792% |
| BioStem Technologies, Inc. | 15.9 Million USD | 86.702% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -355.148% |
| LadRx Corporation | 2.2 Million USD | 3.884% |
| Cell Source, Inc. | 15.8 Million USD | 86.619% |
| Regen BioPharma, Inc. | 5.45 Million USD | 61.246% |
| Regen BioPharma, Inc. | 5.45 Million USD | 61.246% |
| NovAccess Global Inc. | 7.86 Million USD | 73.093% |
| Affymax, Inc. | 8.87 Million USD | 76.157% |
| Itoco Inc. | 1.65 Million USD | -27.942% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -3.095% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 65.034% |
| Mobile Lads Corp. | 1.31 Million USD | -61.026% |
| CytoDyn Inc. | 127.89 Million USD | 98.346% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -4960.095% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -35.029% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 80.851% |
| SYBLEU INC | 681.41 Thousand USD | -210.395% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 65.338% |
| International Stem Cell Corporation | 5.27 Million USD | 59.919% |
| Bioxytran, Inc. | 3.24 Million USD | 34.911% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -237.974% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 54.191% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 94.841% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 90.5% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -4.428% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 61.39% |
| Neutra Corp. | 973.52 Thousand USD | -117.258% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 92.71% |
| PureTech Health plc | 125.58 Million USD | 98.316% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 43.705% |
| IXICO plc | 1.9 Million USD | -11.302% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 89.697% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 97.953% |
| CSL Limited | 18.62 Billion USD | 99.989% |
| Cellectis S.A. | 249.36 Million USD | 99.152% |